« President Bush Calls for Full U.N. Oil-For-Food Probe | Main | Daybreak Quick Trip Around The News Circuit »
December 2, 2004
Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions.
Topics: Clinical PharmacologyAbstract Review of Article in process:
Invest New Drugs. 2005 Jan;23(1):11-20. Lansky EP, Jiang W, Mo H, Bravo L, Froom P, Yu W, Harris NM, Neeman I, Campbell MJ., Rimonest Ltd., Horev Center, Box 9945, Haifa, Israel. info@rimonest.com.
We investigated whether dissimilar biochemical fractions originating in anatomically discrete sections of the pomegranate ( Punica granatum ) fruit might act synergistically against proliferation, metastatic potential, and phosholipase A2 (PLA2) expression of human prostate cancer cells in vitro .
Proliferation of DU 145 human prostate cancer cells was measured following treatment with a range of therapeutically active doses of fermented pomegranate juice polyphenols (W) and sub-therapeutic doses of either pomegranate pericarp (peel) polyphenols (P) or pomegranate seed oil (Oil).
Invasion across Matrigel by PC-3 human prostate cancer cells was measured following treatment with combinations of W, P and Oil such that the total gross weight of pomegranate extract was held constant.
Expression of PLA2, associated with invasive potential, was measured in the PC-3 cells after treatment with the same dosage combinations as per invasion. Supra-additive, complementary and synergistic effects were proven in all models by the Kruskal-Wallis non-parametric H test at p < 0.001 for the proliferation tests, p < 0.01 for invasion, and p < 0.05 for PLA2 expression.
Proliferation effects were additionally evaluated with CompuSyn software median effect analysis and showed a concentration index CI < 1, confirming synergy.
The results suggest vertical as
well as the usual horizontal strategies for discovering pharmacological
actives in plants.
PMID: 15528976
Posted by Hyscience at December 2, 2004 10:39 PM
Articles Related to Clinical Pharmacology:
- Britain tests first Cannabis related medicine for rheumatoid arthritis - Nov 13, 2005
- Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma - May 26, 2005
- Cystatin C May Push Creatinine Off Risk Radar - May 19, 2005
- Cancer Treatment Success Stuns Scientists - May 16, 2005
- Antibody, cancer drug combo shows promise against breast tumors - May 16, 2005
- USC researchers determine mechanism of action of motexafin gadolinium (Xcytrin) - May 02, 2005
- Herceptin® Combined With Chemotherapy Improves Disease-Free Survival for Patients With Early-Stage Breast Cancer - Apr 26, 2005
- Selenium will have critical role in prostate cancer treatment - Fox Chase Cancer Center - Apr 21, 2005
- Traditional Medicine Derivatives Kill Cancer Cells - Apr 20, 2005
- Compound from Chinese medicine shows promise in head and neck cancer, U-M study finds - Apr 19, 2005
